Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome.

Megherea, Oxana; Janes, Carmen; Kowalski, Andrew; Baron, Jessica; Ahn, Esther; Soule, Ashley; Newman, Matthew

Megherea, Oxana; Janes, Carmen; Kowalski, Andrew; Baron, Jessica; Ahn, Esther; Soule, Ashley; Newman, Matthew.

Afiliación

Megherea O; Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Janes C; Department of Pharmacy/Oncology Division, The Johns Hopkins Hospital, Baltimore, MD, USA.
Kowalski A; Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, USA.
Baron J; NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY, USA.
Ahn E; Sibley Memorial Hospital, Washington, DC, USA.
Soule A; University of Kentucky HealthCare, Lexington, KY, USA.
Newman M; Department of Pharmacy/Oncology Division, The Johns Hopkins Hospital, Baltimore, MD, USA.

Leuk Lymphoma ; 62(13): 3219-3225, 2021 12.

Article en En | MEDLINE | ID: mdl-34313176

Asunto(s)

Antineoplásicos; Leucemia Mieloide Aguda; Antineoplásicos/uso terapéutico; Inhibidores Enzimáticos/efectos adversos; Humanos; Isocitrato Deshidrogenasa/genética; Leucemia Mieloide Aguda/diagnóstico; Mutación; Estudios Retrospectivos; Síndrome

Palabras clave

Differentiation syndrome; IDH inhibitor; IDH-DS; acute myeloid leukemia; enasidenib; ivosidenib

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Leucemia Mieloide Aguda / Antineoplásicos Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google